Structure Therapeutics (NASDAQ:GPCR) Trading Up 6.2% – Should You Buy?

Structure Therapeutics Inc. (NASDAQ:GPCR) shares traded up 6.2% during mid-day trading on Friday . The company traded as high as $24.84 and last traded at $24.84. 320,756 shares were traded during trading, a decline of 58% from the average session volume of 772,438 shares. The stock had previously closed at $23.39.

Analyst Ratings Changes

A number of equities analysts recently issued reports on the company. JMP Securities restated a “market outperform” rating and set a $91.00 price objective on shares of Structure Therapeutics in a report on Wednesday, December 18th. Stifel Nicolaus started coverage on Structure Therapeutics in a research report on Wednesday, January 8th. They set a “buy” rating and a $50.00 target price for the company. Finally, HC Wainwright reaffirmed a “buy” rating and set a $80.00 target price on shares of Structure Therapeutics in a research report on Thursday, December 19th. Eight investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $81.29.

Structure Therapeutics Trading Up 1.3 %

The stock has a market capitalization of $1.36 billion, a P/E ratio of -32.61 and a beta of -2.75. The company has a 50-day moving average price of $27.52 and a 200 day moving average price of $34.11.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in GPCR. Bank Pictet & Cie Europe AG bought a new position in shares of Structure Therapeutics in the 3rd quarter worth $206,000. Mirae Asset Global Investments Co. Ltd. increased its position in Structure Therapeutics by 60.1% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,784 shares of the company’s stock valued at $158,000 after buying an additional 1,420 shares in the last quarter. abrdn plc increased its position in Structure Therapeutics by 132.7% during the 3rd quarter. abrdn plc now owns 217,083 shares of the company’s stock valued at $9,528,000 after buying an additional 123,789 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its position in Structure Therapeutics by 99.2% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 11,460 shares of the company’s stock valued at $503,000 after buying an additional 5,707 shares in the last quarter. Finally, Janney Capital Management LLC acquired a new position in Structure Therapeutics during the 3rd quarter valued at about $290,000. 91.78% of the stock is owned by institutional investors.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.